Literature DB >> 16901958

Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies.

Richard Watts1, Suzanne Lane, Thomas Hanslik, Thomas Hauser, Bernhard Hellmich, Wenche Koldingsnes, Alfred Mahr, Mårten Segelmark, Jan W Cohen-Tervaert, David Scott.   

Abstract

BACKGROUND: The classification of antineutrophil cytoplasmic antibody-associated vasculitis (AAV) and polyarteritis nodosa (PAN) for epidemiology studies is confusing. The existing schemes such as American College of Rheumatology (ACR) criteria, Chapel Hill Consensus Conference (CHCC) definitions and Lanham criteria produce overlapping and conflicting classifications, making it difficult to compare incidence figures. AIM: To develop a consensus method of using these criteria and definitions for epidemiological studies to permit comparison without confounding by classification.
METHODS: A stepwise algorithm was developed by consensus between a group of doctors interested in the epidemiology of vasculitis. The aim was to categorise patients with Wegener's granulomatosis, microscopic polyangiitis (MPA), Churg-Strauss syndrome (CSS) and PAN into single clinically relevant categories. The ACR and Lanham criteria for CSS, and ACR criteria for Wegener's granulomatosis were applied first, as these were considered to be the most specific. Surrogate markers for Wegener's granulomatosis were included to distinguish Wegener's granulomatosis from MPA. MPA was classified using the CHCC definition and surrogate markers for renal vasculitis. Finally, PAN was classified using the CHCC definition. The algorithm was validated by application to 20 cases from each centre and 99 from a single centre, followed by a paper case exercise.
RESULTS: A four-step algorithm was devised. It successfully categorises patients into a single classification. There was good correlation between observers in the paper case exercise (91.5%; unweighted kappa = 0.886).
CONCLUSION: The algorithm achieves its aim of reliably classifying patients into a single category. The use of the algorithm in epidemiology studies should permit comparison between geographical areas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16901958      PMCID: PMC1798520          DOI: 10.1136/ard.2006.054593

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  15 in total

1.  A prospective study of vasculitis patients collected in a five year period: evaluation of the Chapel Hill nomenclature.

Authors:  S F Sørensen; O Slot; N Tvede; J Petersen
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

2.  The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis.

Authors:  R Y Leavitt; A S Fauci; D A Bloch; B A Michel; G G Hunder; W P Arend; L H Calabrese; J F Fries; J T Lie; R W Lightfoot
Journal:  Arthritis Rheum       Date:  1990-08

3.  The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary.

Authors:  J F Fries; G G Hunder; D A Bloch; B A Michel; W P Arend; L H Calabrese; A S Fauci; R Y Leavitt; J T Lie; R W Lightfoot
Journal:  Arthritis Rheum       Date:  1990-08

4.  The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis).

Authors:  A T Masi; G G Hunder; J T Lie; B A Michel; D A Bloch; W P Arend; L H Calabrese; S M Edworthy; A S Fauci; R Y Leavitt
Journal:  Arthritis Rheum       Date:  1990-08

5.  Polyarteritis nodosa when applying the Chapel Hill nomenclature--a descriptive study on ten patients.

Authors:  D Selga; A Mohammad; G Sturfelt; M Segelmark
Journal:  Rheumatology (Oxford)       Date:  2006-04-04       Impact factor: 7.580

6.  A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.

Authors:  David Jayne; Niels Rasmussen; Konrad Andrassy; Paul Bacon; Jan Willem Cohen Tervaert; Jolanta Dadoniené; Agneta Ekstrand; Gill Gaskin; Gina Gregorini; Kirsten de Groot; Wolfgang Gross; E Christiaan Hagen; Eduardo Mirapeix; Erna Pettersson; Carl Siegert; Alberto Sinico; Vladimir Tesar; Kerstin Westman; Charles Pusey
Journal:  N Engl J Med       Date:  2003-07-03       Impact factor: 91.245

Review 7.  Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases.

Authors:  Judy Savige; Wayne Dimech; Marvin Fritzler; James Goeken; E Chris Hagen; J Charles Jennette; Rob McEvoy; Charles Pusey; Wendy Pollock; Michelle Trevisin; Allan Wiik; Richard Wong
Journal:  Am J Clin Pathol       Date:  2003-09       Impact factor: 2.493

8.  Evaluation of the Sørensen diagnostic criteria in the classification of systemic vasculitis.

Authors:  S E Lane; R A Watts; T H W Barker; D G I Scott
Journal:  Rheumatology (Oxford)       Date:  2002-10       Impact factor: 7.580

Review 9.  Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome.

Authors:  J G Lanham; K B Elkon; C D Pusey; G R Hughes
Journal:  Medicine (Baltimore)       Date:  1984-03       Impact factor: 1.889

10.  The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa.

Authors:  R W Lightfoot; B A Michel; D A Bloch; G G Hunder; N J Zvaifler; D J McShane; W P Arend; L H Calabrese; R Y Leavitt; J T Lie
Journal:  Arthritis Rheum       Date:  1990-08
View more
  338 in total

Review 1.  ANCA-associated vasculitides--advances in pathogenesis and treatment.

Authors:  Min Chen; Cees G M Kallenberg
Journal:  Nat Rev Rheumatol       Date:  2010-10-05       Impact factor: 20.543

2.  [Polyarteritis nodosa: differential diagnostics and therapy].

Authors:  J H Schirmer; K Holl-Ulrich; F Moosig
Journal:  Z Rheumatol       Date:  2014-12       Impact factor: 1.372

Review 3.  ANCA-associated small vessel vasculitis: clinical and therapeutic advances.

Authors:  Niveditha Mohan; Gail S Kerr
Journal:  Curr Rheumatol Rep       Date:  2010-12       Impact factor: 4.592

4.  HBsAg-negative and anti-HBc-positive in eosinophilic granulomatosis with polyangiitis: a retrospective pilot study.

Authors:  Sang-Won Lee; Do Young Kim; Sang Hoon Ahn; Yong-Beom Park; Kwang-Hyub Han; Jun Yong Park
Journal:  Rheumatol Int       Date:  2018-05-12       Impact factor: 2.631

5.  Association of Cigarette Smoking With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Authors:  Greg McDermott; Xiaoqing Fu; John H Stone; Rachel Wallwork; Yuqing Zhang; Hyon K Choi; Zachary S Wallace
Journal:  JAMA Intern Med       Date:  2020-06-01       Impact factor: 21.873

6.  A myelopoiesis gene signature during remission in anti-neutrophil cytoplasm antibody-associated vasculitis does not predict relapses but seems to reflect ongoing prednisolone therapy.

Authors:  T Kurz; M Weiner; C Skoglund; S Basnet; P Eriksson; M Segelmark
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

Review 7.  Vasculitis: do we know more to classify better?

Authors:  Ezgi Deniz Batu; Seza Ozen
Journal:  Pediatr Nephrol       Date:  2014-12-06       Impact factor: 3.714

8.  Clinical significance of ANCA positivity in patients with IgA vasculitis: a retrospective monocentric study.

Authors:  Jae Yeon Kim; Hyeok Choi; Minyoung Kevin Kim; Soo Bin Lee; Yong-Beom Park; Sang-Won Lee
Journal:  Rheumatol Int       Date:  2019-08-01       Impact factor: 2.631

Review 9.  Clinical studies of the Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan.

Authors:  Hirofumi Makino; Ken-Ei Sada
Journal:  Clin Exp Nephrol       Date:  2013-10-05       Impact factor: 2.801

10.  Incidence and risk factors of new-onset hypertrophic pachymeningitis in patients with anti-neutrophil antibody-associated vasculitis: using logistic regression and classification tree analysis.

Authors:  Aya Imafuku; Naoki Sawa; Masahiro Kawada; Rikako Hiramatsu; Eiko Hasegawa; Masayuki Yamanouchi; Junichi Hoshino; Yoshihumi Ubara; Kenmei Takaichi
Journal:  Clin Rheumatol       Date:  2018-11-27       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.